Printer Friendly

Near-Term Launches of Oral Agents for Venous Thromboembolism (VTE) Treatment/Secondary Prophylaxis Will Trigger a Sharp Decline in the Fortunes of Low-Molecular-Weight Heparins and Vitamin K Antagonists.

Bayer/Janssen's Xarelto Will Be the Sales-Leading Therapy Among Novel Oral Anticoagulants in the Combined VTE Markets, According to Findings from Decision Resources

BURLINGTON, Mass. -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market shares of low-molecular-weight heparins and vitamin K antagonists continue to be gradually eroded by the uptake of novel oral anticoagulants in Europe for venous thromboembolism (VTE) prevention after orthopedic surgery. The near-term launches of oral agents for VTE treatment/secondary prophylaxis will trigger a sharp decline in the fortunes of low-molecular-weight heparins and vitamin K antagonists. In 2011, low-molecular-weight heparins and vitamin K antagonists were the leading therapies for VTE treatment/secondary prophylaxis and primary prophylaxis.

The Pharmacor advisory service entitled Venous Thromboembolism projects that the combined markets for drugs used in the primary prophylaxis of the disease as well as acute treatment and secondary prophylaxis of VTE will increase moderately from $4.1 billion in 2011 to $5.1 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Bayer/Janssen's Xarelto will be the sales-leading therapy among novel oral anticoagulants in the combined VTE markets. Xarelto benefits from impressive Phase III data, its potential to replace the need for both parenteral anticoagulants and vitamin K antagonists for VTE treatment/secondary prophylaxis, and once-daily dosing. Bristol-Myers Squibb/Pfizer's Eliquis will be Xarelto's closest competitor, but later launches and its twice-daily dosing will limit its sales during through 2021.

The findings also reveal that the commercial potential of the VTE prophylaxis market has been significantly reduced following the failures of Xarelto and Eliquis in clinical trials for VTE prevention in medically ill patients.

"These events have dampened the prospects of other oral anticoagulants aiming to enter this indication and have realigned the growth drivers of the combined VTE markets firmly toward the VTE treatment/secondary prophylaxis indication," said Decision Resources Therapeutic Area Director Nikhil Mehta.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 20, 2012
Previous Article:Amber Road Receives New Jersey Technology Council's Large Company of the Year Award.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters